William Diehl

Dr. William Diehl

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Cell
Verified
Journal Article
Closed access
WDWilliam Diehl
William Diehl
ALAaron E. Lin
Aaron E. Lin
NGNathan D. Grubaugh
Nathan D. Grubaugh
LCLuiz Max Carvalho
Luiz Max Carvalho
KKKyusik Kim
Kyusik Kim
JLJeremy Luban
Jeremy Luban

12 December 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
RNRuchi M. Newman
Ruchi M. Newman
LHLaura Hall
Laura Hall
MCMichelle Connole
Michelle Connole
GCGuo-Lin Chen
Guo-Lin Chen
SSShuji Sato
Shuji Sato
WJWelkin E. Johnson
Welkin E. Johnson
Retroviral restriction factor TRIM5α exhibits a high degree of sequence variation among primate species. It has been proposed that this diversity is the cumulative result of ancient, lineage-specific episodes of positive selection. Here, we describe the contribution of within-species variation to the evolution of TRIM5α. Sampling within two geographically distinct Old World monkey species revealed extensive polymorphism, including individual polymorphisms that predate speciation (shared polymorphism). In some instances, alleles were more closely related to orthologues of other species than to one another. Both silent and nonsynonymous changes clustered in two domains. Functional assays revealed consequences of polymorphism, including differential restriction of a small panel of retroviruses by very similar alleles. Together, these features indicate that the primate TRIM5α locus has evolved under balancing selection. Except for the MHC there are few, if any, examples of long-term balancing selection in primates. Our results suggest a complex evolutionary scenario, in which fixation of lineage-specific adaptations is superimposed on a subset of critical polymorphisms that predate speciation events and have been maintained by balancing selection for millions of years.

8 October 2018 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
LYLeonid Yurkovetskiy
Leonid Yurkovetskiy
MGMehmet Hakan Guney
Mehmet Hakan Guney
KKKyusik Kim
Kyusik Kim
SGShih Lin Goh
Shih Lin Goh
SMSean McCauley
Sean McCauley
JLJeremy Luban
Jeremy Luban

21 October 2019 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
KKKyusik Kim
Kyusik Kim
ADAnn Dauphin
Ann Dauphin
SKSevnur Komurlu
Sevnur Komurlu
SMSean M. McCauley
Sean M. McCauley
LYLeonid Yurkovetskiy
Leonid Yurkovetskiy
JLJeremy Luban
Jeremy Luban

13 December 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSean Matthew McCauley
Sean Matthew McCauley
KKKyusik Kim
Kyusik Kim
ANAnetta Nowosielska
Anetta Nowosielska
ADAnn Dauphin
Ann Dauphin
LYLeonid Yurkovetskiy
Leonid Yurkovetskiy
JLJeremy Luban
Jeremy Luban
HIV-1-infected people who take drugs that suppress viremia to undetectable levels are protected from developing AIDS. Nonetheless, HIV-1 establishes proviruses in long-lived CD4+ memory T cells, and perhaps other cell types, that preclude elimination of the virus even after years of continuous antiviral therapy. Here we show that the HIV-1 provirus activates innate immune signaling in isolated dendritic cells, macrophages, and CD4+ T cells. Immune activation requires transcription from the HIV-1 provirus and expression of CRM1-dependent, Rev-dependent, RRE-containing, unspliced HIV-1 RNA. If rev is provided in trans, all HIV-1 coding sequences are dispensable for activation except those cis-acting sequences required for replication or splicing. Our results indicate that the complex, post-transcriptional regulation intrinsic to HIV-1 RNA is detected by the innate immune system as a danger signal, and that drugs which disrupt HIV-1 transcription or HIV-1 RNA metabolism would add qualitative benefit to current antiviral drug regimens.

10 February 2020 in PLOS Biology
Verified
Journal Article
Open access
PDF file
DDDibyendu Kumar Das
Dibyendu Kumar Das
UBUriel Bulow
Uriel Bulow
WDWilliam Diehl
William Diehl
NDNatasha D Durham
Natasha D Durham
FSFernando Senjobe
Fernando Senjobe
JMJames Munro
James Munro
The Ebola virus (EBOV) envelope glycoprotein (GP) is a membrane fusion machine required for virus entry into cells. Following endocytosis of EBOV, the GP1 domain is cleaved by cellular cathepsins in acidic endosomes, removing the glycan cap and exposing a binding site for the Niemann-Pick C1 (NPC1) receptor. NPC1 binding to cleaved GP1 is required for entry. How this interaction translates to GP2 domain-mediated fusion of viral and endosomal membranes is not known. Here, using a bulk fluorescence dequenching assay and single-molecule Förster resonance energy transfer (smFRET)-imaging, we found that acidic pH, Ca2+, and NPC1 binding synergistically induce conformational changes in GP2 and permit virus-liposome lipid mixing. Acidic pH and Ca2+ shifted the GP2 conformational equilibrium in favor of an intermediate state primed for NPC1 binding. Glycan cap cleavage on GP1 enabled GP2 to transition from a reversible intermediate to an irreversible conformation, suggestive of the postfusion 6-helix bundle; NPC1 binding further promoted transition to the irreversible conformation. Thus, the glycan cap of GP1 may allosterically protect against inactivation of EBOV by premature triggering of GP2.